Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex
Executive Summary
Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.
You may also be interested in...
Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro
Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.
Rite Aid To Gain Specialty Drug, Part D Platforms With PBM EnvisionRx
The drug store chain will purchase EnvisionRx, which serves over 21 million members and expects to manage 145 million pharmacy claims in 2015, for $2 billion in cash and stock.